Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision ‐making in otherwise low or intermediate‐1 risk patients with myelofibrosis
Source: British Journal of Haematology - Category: Hematology Authors: Ayalew Tefferi, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh Pardanani Tags: Correspondence Source Type: research
More News: Hematology | UK Health